
In an Instagram post shared Monday, Indian writer Tahira Kashyap revealed that she has been diagnosed with breast cancer for the second time. "Seven-year itch or the power of regular screening - it's a perspective. I prefer going with the latter and suggest the same for everyone who needs to get regular mammograms. Round 2 for me. I still got this," the post read.
In the caption, she reflected on her journey with the disease. "When life gives you lemons, make lemonade. When life becomes too generous and throws them again at you, you squeeze them calmly into your favourite drink and sip it with all the good intentions. Because for one, it's a better drink, and two, you know you will give it your best once again."
Tahira vowed not to shy away from talking about breast cancer or her relapse. "Ironically or not, today is World Health Day. Let's do whatever we can in our capacity to take care of ourselves. Gratitude through and through."
Actor-husband Ayushmann Khurrana acknowledged his wife's struggles in the comments section, where he simply wrote, "My hero." The two have been married since 2008 and have a son and a daughter together.
As per Times of India, Tahira was first diagnosed with breast cancer in 2019. In her podcast My Ex-Breast, Ayushmann shared how he had reacted to the news. "I was hiding behind a pillar, the security guy, and feeling terrible. We were together in Delhi when we got to know about it from a doctor. We didn't know at all. There was a time when both of us were very vulnerable, sitting in a hospital. People were asking for pictures where we were sitting," he said.
Praising his wife's resilience, he added, "We were together in this fight, but I was getting so inspired by her that she probably became stronger than me. She has a great presence. It doesn't come from her hairstyle, it comes from her chanting, practice, the person she has become, her experiences in life, and the sum of everything."
COMMENTS
Comments are moderated and generally will be posted if they are on-topic and not abusive.
For more information, please see our Comments FAQ